1 |
Barker E, Campbell S, Tebb A, Neiger R, Herrtage M, Reid S, Ramsey I. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005; 19: 810-815.
DOI
|
2 |
Bell R, Neiger R, McGrotty Y, Ramsey I. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs. Vet Rec 2006; 159: 277-281.
DOI
|
3 |
Boretti F, Musella C, Burkhardt W, Kuemmerle-Fraune C, Riond B, Reusch C, Sieber-Ruckstuhl N. Comparison of two prepill cortisol concentrations in dogs with hypercortisolism treated with trilostane. BMC Vet Res 2018; 14(1): 417.
DOI
|
4 |
Braddock J, Church D, Robertson I, Watson A. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J 2003; 81: 600-607.
DOI
|
5 |
Cook A, Bond K. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism. J Am Vet Med Assoc 2010; 237: 801-805.
DOI
|
6 |
Ettinger S, Feldman E, Cote, E. Textbook of Veterinary Internal Medicine. St. Louis, Missouri: Elsevier. 2017: 1799, 1807.
|
7 |
Feldman E, Nelson R, Reusch C, Scott-Moncrieff J, Behrend E. Canine & Feline Endocrinology. 4th ed. St. Louis, Missouri: Elsevier. 2015: 434.
|
8 |
Fracassi F, Corradini S, Floriano D, Boari A, Aste G, Pietra M, Bergamini P, Dondi F. Progno sticf actors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane. Vet Rec 2014; 176: 49-49.
DOI
|
9 |
Imbe A, Tanimoto K, Inaba Y, Sakai S, Shishikura K, Imbe H, Hanafusa, T. Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps. Endocr J 2018; 65: 521-526.
DOI
|
10 |
Greene CE, Lorenz MD, Munnell JF, Prasse KW, White NA, Bowen JM. Myopathy associated with hyperadrenocorticism in the dog. J Am Vet Med Assoc 1979; 174: 1310-1315.
|
11 |
Macfarlane L, Parkin T, Ramsey I. Pre-trilostane and threehour post-trilostane cortisol to monitor trilostane therapy in dogs. Vet Rec 2016; 179: 597-597.
DOI
|
12 |
McKerrell RE. Myotonia in Man and Animals: Confusing Comparisons. Equine Vet J 1987; 19: 266-267.
DOI
|
13 |
Nagata N, Yuki M. Long-term outcome of myotonia associated with hyperadrenocorticism in 2 dogs. Can Vet J 2015; 56: 931-933.
|
14 |
Neiger R, Hurley K, Ramsey I, O'Connor J, Mooney C. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002; 150: 799-804.
DOI
|
15 |
Nelson R. Small Animal Internal Medicine. 6th ed: Elsevier - Health Science. 2019: 872.
|
16 |
Platt SR, Olby NJ, Small B. BSAVA Manual of Canine and Feline Neurology. Cheltenham: British Small Animal Veterinary Association. 2013: 8, 23, 62.
|
17 |
Swinney G, Foster S, Chruch D, Malik R. Myotonia associated with hyper-adrenocorticism in two dogs. Aust Vet J 1998; 76: 722-724.
DOI
|
18 |
Vaughan M, Feldman E, Hoar B, Nelson R. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc 2008; 232: 1321-1328.
DOI
|
19 |
Wenger M, Sieber-Ruckstuhl NS, Muller C, Reusch CE. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Am J Vet Res 2004; 65: 1245-1250.
DOI
|